HHHaiying Hua

Haiying Hua

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Haiying Hua has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Triptolide combined with arsenic trioxide induces apoptosis of myelodysplastic syndrome cells by inhibiting the NF-κB signaling pathway

    by Li Sheng, Yingying Zhu, Zhiyao Wen, Mingyuan Fang, Siyu Gu, Long Ye, Haiying Hua

    Background: The aim of this study was to delve into the combined effects of triptolide (TL) and arsenic trioxide (ATO) on the proliferation and apoptosis of myelodysplastic syndrome (MDS) cells, in addition to exploring the important role of the NF-κB signaling pathway underlying these combined actions. Methods: The MDS cells SKM-1 were treated with TL, ATO, and TL combined with ATO, respectively. The CCK-8 kit was used to detect proliferation viability in each group. Flow cytometry with Annexin V-FITC/PI double staining was employed to investigate the rate of apoptosis. The expression levels of mRNA and proteins related to apoptotic molecules, along with key molecules of the NF-κB signaling pathway, were meticulously detected in each group by real-time quantitative polymerase chain reaction and western blot. Results: TL in combination with ATO exhibited a pronounced inhibitory effect on the proliferation of SKM-1 cells ( P <.0001), and the combined actions also triggered apoptosis in SKM-1 cells. The proliferation inhibition rate and apoptosis rate of the combined treatment group were significantly elevated compared to those of the individual drug groups ( P <.05). Upon the integration of TL and ATO, the concentration of PARP cleavage protein escalates, and the mRNA and protein expressions of the executioner caspase, including Caspase3 and Caspase8, experience a marked elevation. Conversely, the mRNA and protein expressions of the anti-apoptotic genes Bcl-2, Bcl-XL, and cIAP1 undergo a significant reduction. Conclusion: The combined impact of TL and ATO amplifies the expression of p65 within the canonical NF-κB signaling pathway, while inhibiting the expression of IkBα, p52, and RelB in the noncanonical pathway. The combination effect of TL and ATO markedly suppresses the proliferation of MDS cells and induces apoptosis collaboratively, which potentially occurs through a mechanism by inhibiting the NF-κB signaling pathway.


  • Open Access

    Targeting Wnt/β-catenin signaling enhances the efficacy of anti-CD38 immunotherapy in multiple myeloma

    by Heng Li, Yunguang Chen, Michaela Gregorova, Tingting Yang, Xiayi Zhang, Xiaoyu Yu, Zhen Wang, Haiying Hua, Long Ye, Xiaowei Qi, et al.

  • Open Access

    Relationship between disease perception and feelings of powerlessness in lymphoma patients: the mediating effect of social support and level of hope

    by Yingying Zhu, Haiying Hua, Li Sheng, Jingfen Zhou, Long Ye, Siyu Gu

    Objectives: Lymphoma patients often experience significant physical and psychological stress, with feelings of powerlessness negatively impacting their health. While social support and hope are crucial for improving mood and coping with disease, their mechanisms in relation to disease perception and powerlessness remain unclear. This study aimed to examine the relationship between disease perception and feelings of powerlessness in lymphoma patients, focusing on the mediating roles of social support and hope.Methods: For a cross-sectional design, 311 lymphoma patients were surveyed using the Brief illness perception questionnaire, Powerlessness assessment tool, Social Support Rating Scale, and Herth’s Hope Scale, and were statistically analyzed using the software SPSS 27.0 and PROCESS version 4.1.Results: A correlation was found between the disease perception, social support, hope level, and feeling of powerlessness of lymphoma patients (P < 0.01). There was a positive correlation between perceptions of illness and powerlessness (β= 0.291, P<0.001), and disease perception could influence powerlessness through three indirect pathways: the separate mediating effect of social support [β= 0.057, 95%CI (0.029~0.091)], the separate mediating effect of level of hope [β= 0.07, 95%CI (0.034~ 0.107)], and the chain mediating effect of social support and hope level [β= 0.019, 95%CI (0.008~0.033)]. Social support and level of hope played a partial medium mediating effect in the effect of perceived disease on feelings of powerlessness, accounting for 13.04% and 16.02% of the total effect, respectively, and the chained mediating effect of both accounted for 4.35% of the total effect.Conclusions: Disease perception and powerlessness were positively correlated in lymphoma patients, and in addition, social support and level of hope mediated the relationship. This conclusion provides a theoretical basis and guidance for nursing interventions to reduce powerlessness in lymphoma patients.


  • Open Access

    Targeting the Inflammation–Metabolism Axis in MGUS: Causal Roles of CXCL10 Mediated by Blood Metabolites

    by Siyu Gu, Zhongyuan Wang, Zhiyao Wen, Mingyuan Fang, Long Ye, Jie Jiang, Haiying Hua

    Background: Inflammatory cytokines have been implicated in monoclonal gammopathy of undetermined significance (MGUS), but their causal mechanisms remain unclear. Metabolites play pivotal roles in plasma cell dysregulation, however, their potential mediation effects between cytokines and MGUS are unexplored. We aimed to elucidate causal relationships between inflammatory cytokines and MGUS and identify metabolite‐mediated pathways. Methods: Using genome‐wide association study (GWAS) summary statistics, we performed bidirectional two‐sample Mendelian randomization (MR) to assess causality between 91 inflammatory cytokines and MGUS. A two‐step MR approach was employed to investigate metabolite mediation using data from 1400 blood metabolites. Sensitivity analyses addressed pleiotropy and reverse causality (IVs: p < 1 × 10 −5 , F ‐statistic > 10). Results: MR analysis identified CXCL10 (OR = 2.12, 95% CI: 1.06–4.23, p = 0.034) and IL‐6 (OR = 3.61, 95% CI: 1.22–10.65, p = 0.020) as causal risk factors for MGUS. We also found Threonate (OR = 2.24, 95% CI: 1.06–4.75, p = 0.035), X‐22776 (OR = 3.45, 95% CI: 1.37–8.67, p = 0.009) and glucose to sucrose ratio (OR = 2.89, 95% CI: 1.18–7.07, p = 0.020) were associated with increased MGUS risk, while N‐acetylputrescine to (N(1) + N(8))‐acetylspermidine ratio (OR = 0.65, 95% CI: 0.43–0.98, p = 0.039) showed protective effects. Mediation analysis revealed 2 metabolites Threonate and X‐22776 mediating CXCL10’s effect on MGUS. Threonate mediated 11.2% ( β = 0.08, p = 0.014) and X‐22776 mediated 17.7% ( β = 0.13, p = 0.028) of CXCL10’s total effect. Sensitivity analyses confirmed robustness (no pleiotropy: MR‐Egger intercept p > 0.05; Cochran’s Q p > 0.05). Conclusion: This study deeply reveals the mechanism by which inflammatory cytokines affect the pathogenesis of MGUS through metabolite‐mediated pathways, providing new potential targets for the early diagnosis and treatment of MGUS. In the future, other inflammatory cytokines and metabolites that may be related to the pathogenesis of MGUS can be further explored, and the interactions and potential mechanisms between them can be further studied to provide a more comprehensive theoretical basis and practical guidance for the prevention and treatment of MGUS.

  • Open Access

    PB2050: COMPARISON OF CLINICAL CHARACTERISTICS OF CHILD AND ADULT PATIENTS WITH PNH: ——TEN-YEAR FOLLOW-UP

    by Hui Yang, Jin Li, Yueming Gong, Ninning Wang, Haiying Hua, Xiaoyu Chen, Ting Zhang, Guangsheng He, Jianyong Li

  • Open Access

    A Novel and Validated Inflammation-Based Prognosis Score (IBPS) Predicts Outcomes in Patients with Diffuse Large B-Cell Lymphoma

    by Yajiao Liu, Li Sheng, Haiying Hua, Jingfen Zhou, Ying Zhao, Bei Wang

    Purpose: We aimed to create a novel prognostic score, the inflammation-based prognosis score (IBPS). In addition, we attempted to establish and validate a nomogram to predict the overall survival (OS) of patients with DLBCL. Patients and Methods: We retrospectively investigated the data of 213 patients with DLBCL diagnosed and treated in the Affiliated Hospital of Jiangnan University and used these data to develop nomograms. At the same time, 89 patients diagnosed and treated in Wuxi People’s Hospital Affiliated with Nanjing Medical University from January 2015 to June 2021 were collected as an external validation cohort. We developed IBPS through the least absolute shrinkage and selection operator (LASSO) Cox regression. The univariate and multivariate Cox regression method was used to develop the nomogram. We used the concordance index (C-index), calibration chart, time-dependent receiver operating characteristic (ROC) analysis, decision curve analysis (DCA), and the Kaplan–Meier curve were used to assess the nomogram. Results: The systemic immune inflammation index (SII), prognostic nutrition index (PNI), and modified Glasgow prognostic score (mGPS) were used to construct IBPS. The Eastern Cooperative Oncology Group performance status (ECOG PS), IBPS, response to treatment, and whether accept surgery were used to construct the nomogram to predict the OS of DLBCL patients. The C-index in the training and validation cohorts were 0.844 and 0.828, respectively. According to the time-dependent ROC curve and DCA, the nomogram has good predictive accuracy and clinical net benefit. The Kaplan–Meier curve showed that according to the nomogram score, patients in the training and validation cohorts could be classified into three risk groups. Conclusion: In patients with DLBCL, baseline IBPS was a reliable predictor of OS. The survival probability of DLBCL patients can be precisely predicted using the prognosis nomogram based on IBPS.


  • Open Access

    Analysis of the clinical characteristics and prognosis of adult de novo acute myeloid leukemia (none APL) with PTPN11 mutations

    by Li Sheng, Yajiao Liu, Yingying Zhu, Jingfen Zhou, Haiying Hua

    We discuss the clinical characteristics and prognostic significance of adult individuals with PTPN11 mutations who have developed acute myeloid leukemia (AML) (none acute promyelocytic leukemia). Next generation sequencing and Sanger sequencing were used to detect 51 gene mutations, and multiplex-PCR was used to detect 41 fusion genes from 232 de novo adult AML patients retrospectively. About 7.76% patients harbored PTPN11 mutations, 20 PTPN11 alterations were identified, all of which were missense mutations in the N-SH2 (n = 16) and PTP (n = 4) domains located in exon 3. Patients with PTPN11 mut had significantly higher platelet counts and hemoglobin levels (p < 0.001), which were mainly detected in M5 (n = 12, 66.67%, p < 0.001) subtype. Patients with MLL-AF6 positive showed a higher frequency of PTPN11 mut (p = 0.018) in the 118 AML cases. PTPN11 mut were accompanied by other mutations, which were NPM1 (44.44%), DNMT3A (38.89%), FLT3 (38.89%), and NRAS (17.2%). PTPN11 mut had a negative impact on the complete remission rate in M5 subtype patients (p < 0.001). However, no statistically significant effect on overall survival (OS) with PTPN11 mut patients in the whole cohort and age group (p > 0.05) was observed. Further analysis revealed no significant difference in OS among NPM1 mut/PTPN11 mut, NPM1 mut/PTPN11 wt, DNMT3A mut/PTPN11 mut, and DNMT3A mut/PTPN11 wt patients (p > 0.05). Multivariate analysis showed the proportion of bone marrow blasts ≥65.4% was a factor significantly affecting OS in PTPN11 mut patients (p = 0.043).

  • Open Access

    An Externally Validated Nomogram for Predicting the Overall Survival of Patients With Diffuse Large B-Cell Lymphoma Based on Clinical Characteristics and Systemic Inflammatory Markers

    by Yajiao Liu, Li Sheng, Haiying Hua, Jingfen Zhou, Ying Zhao, Bei Wang

    Background: Systemic inflammatory indicators are clinically significant in guiding diffuse large B-cell lymphoma (DLBCL) prognosis. However, which inflammatory markers are the best predictors of DLBCL prognosis is still unclear. In this study, we aimed to create a nomogram based on the best inflammatory markers and clinical indicators to predict the overall survival of patients with DLBCL. Patients and methods: We analyzed data from 423 DLBCL patients from two institutions and divided them into a training set, an internal validation set, and an external validation set (n = 228, 97, and 98, respectively). The least absolute shrinkage and selection operator and Cox regression analysis were used to develop nomograms. We assessed model fit using the Akaike information criterion and Bayesian information criterion. The concordance index (C-index), calibration curve, receiver operating characteristic (ROC) curve, and decision curve analysis (DCA) were used to assess the nomogram's predictive performance and clinical net benefit and compared with the International Prognostic Index (IPI) and National Comprehensive Cancer Network (NCCN)-IPI. Results: The inclusion variables for the nomogram model were age, Eastern Cooperative Oncology Group performance status, lactate dehydrogenase level, the systemic immune-inflammation index (SII), the prognostic nutritional index (PNI), and β-2 microglobulin (β-2 MG) level. In the training cohort, the nomogram showed better goodness of fit than the IPI and NCCN-IPI. The C-index of the nomogram (0.804, 95% CI: 0.751-0.857) outperformed the IPI (0.690, 95% CI: 0.629-0.751) and NCCN-IPI (0.691, 95% CI: 0.632-0.750). The calibration curve, ROC curve, and DCA curve analysis showed that the nomogram has satisfactory predictive power and clinical utility. Similar results were found in the validation cohort. Conclusion: The nomogram integrated with the clinical characteristics and inflammatory markers is beneficial to predict the prognosis of patients with DLBCL.


    • 1 April 2022
      • Vol. 30  (2) , 351-356

    [Analysis of Coexisting Gene with NRAS in Acute Myeloid Leukemia].

    by Ye-Ping Sheng, Hai-Ying Hua, Hong-Ying Chao, Wen-Yan Zhu, Zhi-Qing Wang, Yan Zhang, Ye Zhou

    To investigate the coexisting mutations and clinical significance of Homo sapiens neuroblastoma RAS viral oncogene homolog (NRAS) gene in acute myeloid leukemia (AML) patients. High-throughput DNA sequencing and Sanger sequencing were used to detect 51 gene mutations. The occurrence, clinical characteristics and treatment efficacy of coexisting genes with NRAS were investigated. A total of 57 NRAS mutations (17.5%) were detected in 326 patients with AML. Compared with the patients in NRAS non-mutation group, patients in the mutant group were younger (P=0.018) and showed lower platelet count (P=0.033), but there was no significant difference in peripheral leukocyte count, hemoglobin, and sex. For FAB classification, NRAS mutation and M2 subtype showed mutually exclusive (P=0.038). Among 57 patients carried with NRAS mutation, 51 (89.5%) patients carried with other gene mutations, 25 (43.9%) carried with double gene mutations, 10 (17.5%) carried with 3 gene mutations, and 16 (28.1%) corried with ≥ 4 gene mutations. The most common coexisting gene mutation was KRAS (24.6%, 14/57), followed by FLT3-ITD (14.0%, 8/57), RUNX1 (12.3%, 7/57), NPM1 (10.5%, 6/57), PTPN11 (10.5%, 6/57), DNMT3A (10.5%, 6/57) and so on. The age (P=0.013, P=0.005) and peripheral platelet count (P=0.007, P=0.021) of patients with NPM1 or DNMT3A mutations were higher than those of the patients with wild type, but there was no significant difference in peripheral leukocyte count and hemoglobin. Also, there was no significant difference in age, peripheral leukocyte count, hemoglobin, and peripheral platelet count between the patients in KRAS, FLT3-ITD, RUNX1 or PTPN11 mutant group and the wild group. Patients with FLT3-ITD mutations showed a lower complete remission (CR) rate (P=0.044). However, there was no significant difference in CR rate between the patients with KRAS, NPM1, RUNX1, PTPN11 or DNMT3A mutations and the wild group. The CR rate of the patents with single gene mutation, double gene mutations, 3 gene mutations, and≥ 4 gene mutations were decreased gradually, and there was no significant difference in CR rate between pairwise comparisons. The mutation rate of NRAS mutation is 17.5%, 89.5% of AML patients with NRAS mutation coexist with additional gene mutations. The type of coexisting mutations has a certain impact on clinical characteristics and CR rate of patients with AML.